Ms Rebecca Collings

Ms Rebecca Collings

Department of Cancer and Genomic Sciences
Trial Management Team Leader

Contact details

Email
r.m.collings@bham.ac.uk
Address
Cancer Research UK Clinical Trials Unit
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Rebecca Collings is the Haematology Team Leader in the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham.

Qualifications

BSc in Biological Sciences, Virginia Polytechnic Institute and State University, 2014

Biography

Rebecca Collings graduated with a Bachelors of Science in Biological Sciences in 2014.

Rebecca has worked in clinical research roles at Aston University, MAC Clinical Research, University of Maryland and Johns Hopkins University. She joined the CRCTU at the University of Birmingham as a Senior Trial Coordinator in 2020 in the Haematology ASCENT team. She was appointed to Haematology Trial Management Team Leader in 2023. Her experience is in both early and late phase trials of haematological malignancies and across paediatric and adult settings.

Teaching

Research

Rebecca Collings has contributed to the design, set-up and/or management of the following trials:

  • AMADEUS (Acute Myeloid Leukaemia/Myelodysplastic Syndrome)
  • COSI (Acute Myeloid Leukaemia/Myelodysplastic Syndrome)
  • COVID19_BMT (COVID19/Haematological Malignancies)
  • MoTD (Graft versus Host Disease)
  • TIDaL (Post transplant Lymphoproliferative disorder)
  • RATinG (Acute Graft versus Host Disease)
  • ALL-RIC (Acute Lymphoblastic Leukaemia)
  • PROMise (Myelofibrosis)
  • PRiZM+ (Primary CNS lymphoma)

Publications

Giovanna Lucchini, Elena Cozma, Aimee Jackson, Kimberly Gilmour, Rachel Elizabeth Protheroe, Eleni Tholouli, Robert F Wynn, Keith Wilson, Karl S Peggs, Victoria Potter, Anne Parker, Charles Craddock, Shankara Paneesha, Emma Nicholson, David I. Marks, Oana Mirci-Danicar, Christopher Parrish, Alexander M Martin, Graham McIlroy, Rebecca Bishop, Rebecca Collings, Ellie Williams, Persis J Amrolia, (23-Nov-2021), COVID-19 Infection of HSCT Recipients Is Associated with High Mortality but No Detectable Cytokine Storm at Presentation, BLOOD 2021, 138 (Supplement 1): 1788. 

Charles Craddock, David Marks, Victoria Potter, Wendy A Ingram, Rebecca Collings, Eleni Tholouli, Rachel Protheroe, Hugh Allen, Alex Ross, Dawn Farrar, Shamyla Siddique, Rebecca Bishop, Ronjon Chakraverty, (02-Nov-2023), The UK Impact Transplant Trials Network: An Effective National Strategy to Accelerate the Delivery of Randomized Trials in Stem Cell Transplantation, BLOOD 2023, 142 (Supplement 1): 5097.

W. Ingram, R. Collings, A. Jackson, R. Protheroe, V. Potter, F. Dignan, E. Hurst, C. Crawley, P. Kottaridis, C. Gaskell, R. Chakraverty, E. Williams, R. Bishop, C. Craddock, (19-23 March 2022), The role of the UK transplant trials network impact in delivering the Amadeus study during the COVID-19 pandemic, EBMT: Data Management Group - Poster Session (P604), Bone Marrow Transplant, 57(Suppl 1):458-461.